Youtor
Rationale for Treating Marginal Zone Lymphoma With PI3KDelta Inhibitor Umbralisib
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=gPE1QiENkeY
Lori A. Leslie, MD, a lymphoma attending at John Theurer Cancer Center, discusses the rationale for investigating the PI3K-delta inhibitor umbralisib (TGR-1202) monotherapy in patients with relapsed/refractory marginal zone lymphoma (MZL) in a multi-center, open-label phase II study. On trial, only patients with MZL were enrolled who had at least 1 prior line of therapy. These patients received single-agent umbralisib once-daily until progression or unacceptable toxicity. • Based on findings reported at the 2019 American Association for Cancer Research (AACR) Annual Meeting, an objective response rate of 52% was demonstrated in this patient population. In addition, Leslie says that 19% of patients also achieved a complete response (CR). • While other PI3K inhibitors can induce stable disease and partial responses in MZL, 19% of patients achieving a CR is higher than what’s been noted historically for this group of agents, Leslie notes. • Umbralisib is a newer-generation PI3K-delta inhibitor. Leslie says that umbralisib inhibits the PI3K-delta isoform, enhances specificity for the delta isoform, and has somewhat of an effect on T-regulatory cell function and numbers. In addition, umbralisib has demonstrated lower safety signals in terms of immune toxicities compared to other PI3K inhibitors, says Leslie. • For more resources and information regarding anticancer targeted therapies in lymphoma: http://targetedonc.com/resource-cente...
#############################
